Protocol for the Examination of Specimens From Patients With Cancers of the Larynx

Version: Larynx 4.0.0.0  Protocol Posting Date: June 2017
Includes pTNM requirements from the 8th Edition, AJCC Staging Manual

For accreditation purposes, this protocol should be used for the following procedures AND tumor types:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Resection</td>
<td>Includes specimens designated larynx, supraglottis, glottis, and subglottis.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinoma</td>
<td>Includes squamous cell carcinoma, neuroendocrine carcinoma, and minor salivary gland carcinoma</td>
</tr>
<tr>
<td>Mucosal Melanoma</td>
<td></td>
</tr>
</tbody>
</table>

This protocol is NOT required for accreditation purposes for the following:

<table>
<thead>
<tr>
<th>Procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopsy</td>
</tr>
<tr>
<td>Primary resection specimen with no residual cancer (e.g., following neoadjuvant therapy)</td>
</tr>
<tr>
<td>Cytologic specimens</td>
</tr>
</tbody>
</table>

The following tumor types should NOT be reported using this protocol:

<table>
<thead>
<tr>
<th>Tumor Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypopharyngeal squamous cell carcinoma (consider the Pharynx protocol)</td>
</tr>
<tr>
<td>Sarcoma (consider the Soft Tissue protocol)</td>
</tr>
<tr>
<td>Lymphoma (consider the Hodgkin or non-Hodgkin Lymphoma protocols)</td>
</tr>
</tbody>
</table>

Authors
Raja R. Seethala, MD*; Martin J Bullock, MD; Diane L. Carlson, MD; Robert L. Ferris, MD, PhD; Louis B. Harrison, MD; Jonathan B. McHugh, MD; Jason Pettus, MD; Mary S. Richardson, MD; Jatin Shah, MD; Lester D.R. Thompson, MD; Ilan Weinreb, MD; Bruce M. Wenig MD

With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.
* Denotes primary authors. All other contributing authors are listed alphabetically.
Accreditation Requirements
This protocol can be utilized for a variety of procedures and tumor types for clinical care purposes. For accreditation purposes, only the definitive primary cancer resection specimen is required to have the core and conditional data elements reported in a synoptic format.

Core data elements are required in reports to adequately describe appropriate malignancies. For accreditation purposes, essential data elements must be reported in all instances, even if the response is "not applicable" or "cannot be determined."

Conditional data elements are only required to be reported if applicable as delineated in the protocol. For instance, the total number of lymph nodes examined must be reported, but only if nodes are present in the specimen.

Optional data elements are identified with “+” and although not required for CAP accreditation purposes, may be considered for reporting as determined by local practice standards.

The use of this protocol is not required for recurrent tumors or for metastatic tumors that are resected at a different time than the primary tumor. Use of this protocol is also not required for pathology reviews performed at a second institution (ie, secondary consultation, second opinion, or review of outside case at second institution).

Synoptic Reporting
All core and conditionally required data elements outlined on the surgical case summary from this cancer protocol must be displayed in synoptic report format. Synoptic format is defined as:

- Data element: followed by its answer (response), outline format without the paired “Data element: Response” format is NOT considered synoptic.
- The data element must be represented in the report as it is listed in the case summary. The response for any data element may be modified from those listed in the case summary, including “Cannot be determined” if appropriate.
- Each diagnostic parameter pair (Data element: Response) is listed on a separate line or in a tabular format to achieve visual separation. The following exceptions are allowed to be listed on one line:
  - Anatomic site or specimen, laterality, and procedure
  - Pathologic Stage Classification (pTNM) elements
  - Negative margins, as long as all negative margins are specifically enumerated where applicable
- The synoptic portion of the report can appear in the diagnosis section of the pathology report, at the end of the report or in a separate section, but all Data element: Responses must be listed together in one location Organizations and pathologists may choose to list the required elements in any order, use additional methods in order to enhance or achieve visual separation, or add optional items within the synoptic report. The report may have required elements in a summary format elsewhere in the report IN ADDITION TO but not as replacement for the synoptic report i.e. all required elements must be in the synoptic portion of the report in the format defined above.

CAP Laboratory Accreditation Program Protocol Required Use Date: March 2018*

* Beginning January 1, 2018, the 8th edition AJCC Staging Manual should be used for reporting pTNM.

CAP Larynx Protocol Summary of Changes

The following data elements were modified:
Pathologic Stage Classification (pTNM, AJCC 8th Edition)

The following data elements were deleted:
Tumor Description
Microscopic Extent of Tumor
Treatment Effect
Clinical History
<table>
<thead>
<tr>
<th>Procedure (select all that apply)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>___ Excision</td>
<td></td>
</tr>
<tr>
<td>___ Endolaryngeal excision</td>
<td></td>
</tr>
<tr>
<td>___ Transoral laser excision (glottis)</td>
<td></td>
</tr>
<tr>
<td>___ Supraglottic laryngectomy</td>
<td></td>
</tr>
<tr>
<td>___ Supracricoid laryngectomy</td>
<td></td>
</tr>
<tr>
<td>___ Vertical hemilaryngectomy (specify side):</td>
<td></td>
</tr>
<tr>
<td>___ Partial laryngectomy (specify type):</td>
<td></td>
</tr>
<tr>
<td>___ Total laryngectomy</td>
<td></td>
</tr>
<tr>
<td>___ Neck (lymph node) dissection (specify):</td>
<td></td>
</tr>
<tr>
<td>___ Other (specify):</td>
<td></td>
</tr>
<tr>
<td>___ Not specified</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumor Site (Note A)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>___ Larynx, supraglottis</td>
<td></td>
</tr>
<tr>
<td>+ ___ Epiglottis, lingual aspect</td>
<td></td>
</tr>
<tr>
<td>+ ___ Epiglottis, laryngeal aspect</td>
<td></td>
</tr>
<tr>
<td>+ ___ Aryepiglottic folds</td>
<td></td>
</tr>
<tr>
<td>+ ___ Arytenoid(s)</td>
<td></td>
</tr>
<tr>
<td>+ ___ False vocal cord</td>
<td></td>
</tr>
<tr>
<td>+ ___ Ventricle</td>
<td></td>
</tr>
<tr>
<td>___ Larynx, glottis</td>
<td></td>
</tr>
<tr>
<td>+ ___ True vocal cord</td>
<td></td>
</tr>
<tr>
<td>+ ___ Anterior commissure</td>
<td></td>
</tr>
<tr>
<td>+ ___ Posterior commissure</td>
<td></td>
</tr>
<tr>
<td>+ ___ With subglottic extension</td>
<td></td>
</tr>
<tr>
<td>___ Larynx, subglottis</td>
<td></td>
</tr>
<tr>
<td>___ Other (specify):</td>
<td></td>
</tr>
<tr>
<td>___ Not specified</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Transglottic Extension</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>___ Present</td>
<td></td>
</tr>
<tr>
<td>___ Not identified</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumor Laterality (select all that apply)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>___ Right</td>
<td></td>
</tr>
<tr>
<td>___ Left</td>
<td></td>
</tr>
<tr>
<td>___ Midline</td>
<td></td>
</tr>
<tr>
<td>___ Not specified</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumor Focality</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>___ Unifocal</td>
<td></td>
</tr>
<tr>
<td>___ Multifocal</td>
<td></td>
</tr>
<tr>
<td>___ Cannot be determined</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumor Size</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Greatest dimension (centimeters): ___ cm</td>
<td></td>
</tr>
</tbody>
</table>

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
+ Additional dimensions (centimeters): ___ x ___ cm
___ Cannot be determined (explain): ____________________________

Histologic Type (Note B)

Squamous Cell Carcinoma and Variants (select all that apply)
___ Squamous cell carcinoma, conventional (keratinizing)
___ Squamous cell carcinoma, nonkeratinizing
___ Acantholytic squamous cell carcinoma
___ Adenosquamous carcinoma
___ Basaloid squamous cell carcinoma
___ Papillary squamous cell carcinoma
___ Spindle cell squamous cell carcinoma
___ Verrucous squamous cell carcinoma
___ Lymphoepithelial carcinoma

Carcinomas of Minor Salivary Glands
___ Mucoepidermoid carcinoma, low grade
___ Mucoepidermoid carcinoma, intermediate grade
___ Mucoepidermoid carcinoma, high grade
___ Adenoid cystic carcinoma, tubular pattern#
  + Specify percentage of solid component: ____%
___ Adenoid cystic carcinoma, cribriform pattern#
  + Specify percentage of solid component: ____%
___ Adenoid cystic carcinoma, solid pattern#
  + Specify percentage of solid component: ____%
___ Adenocarcinoma, not otherwise specified, low grade
___ Adenocarcinoma, not otherwise specified, intermediate grade
___ Adenocarcinoma, not otherwise specified, high grade

# Note: If multiple patterns present, select predominant pattern unless solid pattern is greater than 30%, in which case should select solid pattern.

Neuroendocrine Carcinoma
___ Well-differentiated neuroendocrine carcinoma (typical carcinoid tumor)
___ Moderately differentiated neuroendocrine carcinoma (atypical carcinoid tumor)
___ Poorly differentiated neuroendocrine carcinoma, small cell type
___ Poorly differentiated neuroendocrine carcinoma, large cell type
___ Combined (or composite) neuroendocrine carcinoma with (specify types): ____________________________
___ Mucosal melanoma
___ Carcinoma, type cannot be determined
___ Other histologic type not listed (specify): ____________________________

Histologic Grade (Note C) (required for squamous cell carcinoma only)
___ G1:  Well differentiated
___ G2:  Moderately differentiated
___ G3:  Poorly differentiated
___ Other (specify): ____________________________
___ GX: Cannot be assessed

+ Tumor Extension (other structures/spaces involved)
+ Specify: ____________________________

Margins (select all that apply) (Notes D and E)
___ Cannot be assessed

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
___ Uninvolved by invasive tumor
   Distance from closest margin (millimeters): ____ mm
   Specify location of closest margin, per orientation, if possible: ____________________________
   + Location and distance of other close margins: ____________________________
___ Involved by invasive tumor
   Specify margin(s), per orientation, if possible: ____________________________
___ Uninvolved by high-grade dysplasia/in situ disease#
   Distance from closest margin (millimeters): ____ mm
   Specify location of closest margin, per orientation, if possible: ____________________________
___ Involved by high-grade dysplasia/in situ disease#
   Specify margin(s), per orientation, if possible: ____________________________

# Note: Applicable only to squamous cell carcinoma and histologic variants, and required only if margins uninvolved by invasive carcinoma.

Lymphovascular Invasion
___ Not identified
___ Present
___ Cannot be determined

Perineural Invasion (Note F)
___ Not identified
___ Present
___ Cannot be determined

Regional Lymph Nodes (Note G)
___ No lymph nodes submitted or found

Lymph Node Examination (required only if lymph nodes present in specimen)

Number of Lymph Nodes Involved: ________
___ Number cannot be determined (explain): ____________________________

Number of Lymph Nodes Examined: ________
___ Number cannot be determined (explain): ____________________________

Lymph Node Metastasis (required for all histologies except mucosal melanoma, and only if lymph nodes involved)

Laterality of Lymph Nodes Involved
___ Ipsilateral (including midline)
___ Contralateral
___ Bilateral
___ Cannot be determined

Size of Largest Metastatic Deposit (centimeters): ____ cm

Extranodal Extension (ENE)
___ Not identified
___ Present
   + Distance from lymph node capsule (millimeters): ____ mm
   + ENEma (>2 mm)
   + ENEmi (≤2 mm)
___ Cannot be determined

Pathologic Stage Classification (pTNM, AJCC 8th Edition) (Note H)

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
Note: Reporting of pT, pN, and (when applicable) pM categories is based on information available to the pathologist at the
time the report is issued. Only the applicable T, N, or M category is required for reporting; their definitions need not be
included in the report. The categories (with modifiers when applicable) can be listed on 1 line or more than 1 line.
Note: The phrases in italics include clinical findings required for AJCC staging. This clinical information may not be available
to the pathologist. However, if known, these findings should be incorporated into the pathologic staging.

TNM Descriptors (required only if applicable) (select all that apply)
___ m (multiple primary tumors)
___ r (recurrent)
___ y (posttreatment)

For All Carcinomas

Primary Tumor (pT)
___ pTX: Primary tumor cannot be assessed
___ pTis: Carcinoma in situ

For the Supraglottis
___ pT1: Tumor limited to one subsite of supraglottis with normal vocal cord mobility
___ pT2: Tumor invades mucosa of more than one adjacent subsite of supraglottis or glottis or region outside
the supraglottis (eg, mucosa of base of tongue, vallecula, medial wall of pyriform sinus) **without**
fixation of the larynx
___ pT3: Tumor limited to larynx with vocal cord fixation and/or invades any of the following: postcricoid area,
preepiglottic space, paraglottic space, and/or inner cortex of thyroid cartilage
___ pT4: Moderately advanced or very advanced
___ pT4a: Moderately advanced local disease. Tumor invades through the outer cortex thyroid cartilage and/or
invades tissues beyond the larynx (eg, trachea, soft tissues of neck including deep extrinsic muscle of
tongue, strap muscles, thyroid, or esophagus)
___ pT4b: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades
mediastinal structures

For the Glottis
___ pT1: Tumor limited to the vocal cord(s) (may involve anterior or posterior commissure) with normal mobility
___ pT1a: Tumor limited to one vocal cord
___ pT1b: Tumor involves both vocal cords
___ pT2: Tumor extends to supraglottis and/or subglottis and/or with impaired vocal cord mobility
___ pT3: Tumor limited to the larynx with vocal cord fixation and/or invasion of paraglottic space and/or inner
cortex of the thyroid cartilage
___ pT4: Moderately advanced or very advanced
___ pT4a: Moderately advanced local disease. Tumor invades through the outer cortex of the thyroid cartilage
and/or invades tissues beyond the larynx (eg, trachea, cricoid cartilage, soft tissues of neck including
deep extrinsic muscle of the tongue, strap muscles, thyroid, or esophagus)
___ pT4b: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades
mediastinal structures

For the Subglottis
___ pT1: Tumor limited to subglottis
___ pT2: Tumor extends to vocal cord(s) with normal or impaired mobility
___ pT3: Tumor limited to larynx with vocal cord fixation and/or invasion of paraglottic space and/or inner cortex
of the thyroid cartilage
___ pT4: Moderately advanced or very advanced
___ pT4a: Moderately advanced local disease. Tumor invades cricoid or thyroid cartilage and/or invades tissues
beyond the larynx (eg, trachea, soft tissues of neck including deep extrinsic muscles of the tongue,
strap muscles, thyroid, or esophagus)
___ pT4b: Very advanced local disease. Tumor invades prevertebral space, encases carotid artery, or invades
mediastinal structures

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be
clinically important but are not yet validated or regularly used in patient management.
Regional Lymph Nodes (pN)\(^\#\) (Note G)

- **pNX:** Regional lymph nodes cannot be assessed
- **pN0:** No regional lymph node metastasis
- **pN1:** Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(−)
- **pN2:**
  - Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or
  - metastasis in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(−); or
  - metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)
- **pN2a:**
  - Metastasis in a single ipsilateral node, 3 cm or smaller in greatest dimension and ENE(+); or
  - metastasis in a single ipsilateral node, larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(−)
- **pN2b:** Metastasis in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(−)
- **pN2c:** Metastasis in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(−)
- **pN3:**
  - Metastasis in a lymph node, larger than 6 cm in greatest dimension and ENE(−); or
  - metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or
  - metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or
  - a single contralateral node 3 cm or smaller and ENE(+)
- **pN3a:** Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(−)
- **pN3b:**
  - Metastasis in a single ipsilateral node, larger than 3 cm in greatest dimension and ENE(+); or
  - metastases in multiple ipsilateral, contralateral, or bilateral lymph nodes and any with ENE(+); or
  - a single contralateral node 3 cm or smaller and ENE(+)

\(^\#\) Midline nodes are considered ipsilateral nodes.

Note: Pathological ENE should be recorded as ENE(−) or ENE(+).

Note: Measurement of the metastatic focus in the lymph nodes is based on the largest metastatic deposit size, which may include matted or fused lymph nodes.

Distant Metastasis (pM) (required only if confirmed pathologically in this case)

- **pM1:** Distant metastasis
  
  Specify site(s), if known: ____________________________

For Mucosal Melanoma

Primary Tumor (pT)

- **pT3:** Tumors limited to the mucosa and immediately underlying soft tissue, regardless of thickness or greatest dimension; for example, polypoid nasal disease, pigmented or nonpigmented lesions of the oral cavity, pharynx, or larynx
- **pT4:** Moderately advanced or very advanced disease
- **pT4a:** Moderately advanced disease
  - Tumor involving deep soft tissue, cartilage, bone, or overlying skin
- **pT4b:** Very advanced disease
  - Tumor involving brain, dura, skull base, lower cranial nerves (IX, X, XI, XII), masticator space, carotid artery, prevertebral space, or mediastinal structures

Regional Lymph Nodes (pN)

- **pNX:** Regional lymph nodes cannot be assessed
- **pN0:** No regional lymph node metastases
- **pN1:** Regional lymph node metastases present

Distant Metastasis (pM) (required only if confirmed pathologically in this case)

- **pM1:** Distant metastasis present

+ Data elements preceded by this symbol are not required for accreditation purposes. These optional elements may be clinically important but are not yet validated or regularly used in patient management.
Specify site(s), if known: ____________________________

+ Additional Pathologic Findings (select all that apply) (Note I)
+ ___ None identified
+ ___ Dysplasia, low grade (includes hyperplasia, keratosis, and mild dysplasia)
+ ___ Dysplasia, high grade (includes moderate to severe dysplasia, and carcinoma in situ)
+ ___ Squamous papilloma, solitary
+ ___ Squamous papillomatosis
+ ___ Inflammation (specify type): ____________________________
+ ___ Squamous metaplasia
+ ___ Colonization, fungal
+ ___ Colonization, bacterial
+ ___ Other (specify): ____________________________

+ Ancillary Studies

Note: For reporting molecular testing and other cancer biomarker testing results, the CAP Head and Neck Biomarker Template should be used. Pending biomarker studies should be listed in the Comments section of this report.

+ Comment(s)
Explanatory Notes

Scope of Guidelines
The reporting of laryngeal cancer is facilitated by the provision of a case summary illustrating the features required for comprehensive patient care. However, there are many cases in which the individual practicalities of applying such a case summary may not be straightforward. Common examples include finding the prescribed number of lymph nodes, trying to determine the levels of the radical neck dissection, and determining if isolated tumor cells in a lymph node represent metastatic disease. Case summaries have evolved to include clinical, radiographic, morphologic, immunohistochemical, and molecular results in an effort to guide clinical management. Adjuvant and neoadjuvant therapy can significantly alter histologic findings, making accurate classification an increasingly complex and demanding task. This protocol tries to remain simple while still incorporating important pathologic features as proposed by the American Joint Committee on Cancer (AJCC) cancer staging manual, the World Health Organization (WHO) classification of tumors, the TNM classification,¹ the American College of Surgeons Commission on Cancer, and the International Union on Cancer (UICC). This protocol is to be used as a guide and resource, an adjunct to diagnosing and managing cancers of the larynx in a standardized manner. It should not be used as a substitute for dissection or grossing techniques and does not give histologic parameters to reach the diagnosis. Subjectivity is always a factor, and elements listed are not meant to be arbitrary but are meant to provide uniformity of reporting across all the disciplines that use the information. It is a foundation of practical information that will help to meet the requirements of daily practice to benefit both clinicians and patients alike.

A. Anatomic Sites and Subsites for the Larynx (Figure 1)

Supraglottis
Epilarynx, including marginal zone
  Suprathyroid epiglottis, including tip, lingual (anterior), and laryngeal surfaces
  Aryepiglottic fold, laryngeal aspect
  Arytenoid
Supraglottis, excluding epilarynx
  Infrahyoid epiglottis
  Ventricular bands (false cords)
  Ventriclce

Glottis
Vocal cords
Anterior commissure
Posterior commissure

Subglottis
The protocol applies to all carcinomas arising at these sites.² The piriform sinus represents part of the hypopharynx which expands bilaterally and forward around the sides of the larynx and lies between the larynx and the thyroid cartilage. Cancers of the piriform sinus are included in the protocol on pharynx cancers.

Anatomic Compartments (Figure 1)
The anatomic compartments of the larynx include:

1. Supraglottic larynx extending from the tip of the epiglottis to a horizontal line passing through the apex of the ventricle; structures included in this compartment are the epiglottis (lingual and laryngeal aspects), aryepiglottic folds, arytenoids, false vocal cords and the ventricle.

2. Glottic region, which extends from the ventricle to approximately 0.5 cm to 1.0 cm below the free level of the true vocal cord and includes the anterior and posterior commissures and the true vocal cord.

3. Subglottic larynx, which extends approximately 1.0 cm below the level of the true vocal cord to the inferior rim of the cricoid cartilage.
4. The paraglottic space is a potential space deep to the ventricles and saccules filled with adipose tissue and connective tissue (Figure 2). It is bounded by the conus elasticus inferiorly, the thyroid cartilage laterally, the quadrangular membrane medially, and the piriform sinus posteriorly. Like the paraglottic space, the pre-epiglottic space is filled with adipose tissue and connective tissue (Figure 3); it is triangular in shape and is bounded by the thyroid cartilage and thyrohyoid membrane anteriorly, the epiglottis and thyroepiglottic ligament posteriorly, and the hyoepiglottic ligament at its base (Figures 1 and 2). The paraglottic and preglottic spaces contain lymphatics and blood vessels but no lymph nodes.

Figure 1. Anatomic compartments of the larynx. From Cocke EW Jr, Wang CC. Part I - Cancer of the larynx: selecting optimum treatment. CA Cancer J Clin. 1976;26:194-200. Figure by J.H. Ogura, MD.
Site-Specific Carcinomas

1. Supraglottic squamous cell carcinoma represents a squamous cell carcinoma that involves the structures of the supraglottic larynx, including the epiglottis (laryngeal and lingual surfaces), aryepiglottic folds, arytenoids, false vocal cords, and ventricles.
2. Glottic squamous cell carcinoma represents a squamous cell carcinoma that involves the structures of the glottis, including the true vocal cords, and the anterior and posterior commissures.

3. Subglottic squamous cell carcinoma represents a squamous cell carcinoma that involves the subglottis, which begins 1 cm below the apex of the ventricle to its inferior border represented by the rim of the cricoid cartilage.

4. Transglottic carcinomas represent a carcinoma that crosses the ventricles in a vertical direction arising in either the glottic or supraglottic larynx

B. Histologic Type
A modification of the WHO classification of carcinomas of the larynx is shown below.\(^3,4\) This list may not be complete. This protocol applies to carcinomas and melanomas and does not apply to lymphomas or sarcomas.

Carcinomas of Larynx
Squamous cell carcinoma
- Squamous cell carcinoma, conventional (keratinizing)
- Squamous cell carcinoma, nonkeratinizing
- Adenosquamous carcinoma
- Basaloid squamous cell carcinoma
- Papillary squamous cell carcinoma
- Spindle cell squamous cell carcinoma
- Verrucous squamous cell carcinoma
- Lymphoepithelial carcinoma

Neuroendocrine carcinoma
- Well-differentiated neuroendocrine carcinoma (typical carcinoid tumor)
- Moderately differentiated neuroendocrine carcinoma (atypical carcinoid tumor)
- Poorly differentiated neuroendocrine carcinoma, small cell type
- Poorly differentiated neuroendocrine carcinoma, large cell type
- Combined (or composite) neuroendocrine carcinoma\(^a\)

\(^a\) Represents a carcinoma showing combined features of small cell neuroendocrine carcinoma associated with a squamous or adenocarcinomatous component.

Carcinomas of Minor Salivary Glands
Adenoid cystic carcinoma
Mucoepidermoid carcinoma
Adenocarcinoma, not otherwise specified
Other\(^a\)

\(^a\) Please refer to the CAP protocol for major salivary glands for detailed listing of other tumor types.

Mucosal Melanoma

C. Histologic Grade
For histologic types of carcinomas that are amenable to grading, 3 histologic grades are suggested, as shown below. For conventional squamous cell carcinoma, histologic grading as a whole does not perform well as a prognosticator.\(^5\) Nonetheless, it should be recorded when applicable, as it is a basic tumor characteristic. Selecting either the most prevalent grade or the highest grade for this synoptic protocol is acceptable. Variants of squamous cell carcinoma (ie, verrucous, basaloid, etc) have an intrinsic biologic potential and currently do not appear to require grading.

Grade 1 Well differentiated
Grade 2 Moderately differentiated
Grade 3 Poorly differentiated
Grade X Cannot be assessed
The histologic (microscopic) grading of salivary gland carcinomas has been shown to be an independent predictor of behavior and plays a role in optimizing therapy. Further, there is often a positive correlation between histologic grade and clinical stage. However, most salivary gland carcinoma types have an intrinsic biologic behavior and attempted application of a universal grading scheme is merely a crude surrogate. Thus a generic grading scheme is no longer recommended for salivary gland carcinomas. Carcinoma types for which grading systems exist and are relevant are incorporated into histologic type. The 3 major categories that are amenable to grading include adenoid cystic carcinoma, mucoepidermoid carcinoma, and adenocarcinoma, not otherwise specified.

In some carcinomas, histologic grading may be based on growth pattern, such as in adenoid cystic carcinoma, for which a histologic high-grade variant has been recognized based on the percentage of solid growth. Those adenoid cystic carcinomas showing 30% or greater of solid growth pattern are considered to be histologically high-grade carcinomas. The histologic grading of mucoepidermoid carcinoma includes a combination of growth pattern characteristics (eg, cystic, solid, neurotropism) and cytomorphologic findings (eg, anaplasia, mitoses, necrosis). Adenocarcinomas, not otherwise specified, do not have a formalized grading scheme and are graded intuitively based on cytomorphologic features.

D. Surgical Margins
The definition of a positive margin is somewhat controversial given the varied results from prior studies. However, overall, several studies support the definition of a positive margin to be invasive carcinoma or carcinoma in situ/high-grade dysplasia present at margins (microscopic cut-through of tumor). Furthermore, reporting of surgical margins should also include information regarding the distance of invasive carcinoma, carcinoma in situ, or high-grade dysplasia (moderate to severe) from the surgical margin. Tumors with “close” margins also carry an increased risk for local recurrence. The definition of a “close” margin is not standardized as the effective cut-off varies between studies and between anatomic subsites. Commonly used cut points to define close margins are 5 mm in general and 2 mm with respect to glottic larynx. However, values ranging from 3 mm to 7 mm have been used with success, and for glottic tumors as low as 1 mm. Thus, distance of tumor from the nearest margin should be recorded.

Reporting of surgical margins for carcinomas of the minor salivary glands should follow those used for squamous cell carcinoma of larynx.

Dysplasia
The types of intraepithelial dysplasia of the upper aerodigestive tract (UADT) include nonkeratinizing (“classic”) dysplasia and keratinizing dysplasia. Of the 2 types of dysplasias, the keratinizing dysplasias are significantly more common than the nonkeratinizing dysplasias. The current WHO advocates a 2-tiered approach with low-grade and high-grade dysplasia categories (see below under Note M). High-grade dysplasia at a margin is regarded and reported as a positive margin, while low-grade dysplasia is not.

E. Orientation of Specimen
Complex specimens should be examined and oriented with the assistance of the operating surgeon(s). Direct communication between the surgeon and pathologist is a critical component in specimen orientation and proper sectioning. Whenever possible, the tissue examination request form should include a drawing or photograph of the resected specimen showing the extent of the tumor and its relation to the anatomic structures of the region. The lines and extent of the resection can be depicted on preprinted adhesive labels and attached to the surgical pathology request forms.

F. Perineural Invasion
Traditionally, the presence of perineural invasion (neurotropism) is an important predictor of poor prognosis in head and neck cancer of virtually all sites. The presence of perineural invasion (neurotropism) in the primary cancer is associated with poor local disease control and regional control, as well as being associated with metastasis to regional lymph nodes. Further, perineural invasion is associated with decrease in disease-specific survival and overall survival. There is conflicting data relative to an association between the presence of perineural invasion and the development of distant metastasis, with some studies showing an increased association with distant metastasis, while other studies showing no correlation with distant metastasis. The relationship between perineural invasion and prognosis is independent of nerve diameter. Additionally, emerging evidence suggests that extratumoral perineural invasion may be more prognostically relevant.
perineural invasion of small unnamed nerves may not produce clinical symptoms, the reporting of perineural invasion includes nerves of all sizes including small peripheral nerves (ie, less than 1 mm in diameter). Aside from the impact on prognosis, the presence of perineural invasion also guides therapy. Concurrent adjuvant chemoradiation therapy has been shown to improve outcomes in patients with perineural invasion (as well as in patients with extranodal extension and bone invasion). Given the significance relative to prognosis and treatment, perineural invasion is a required data element in the reporting of head and neck cancers.

G. Lymph Nodes

Measurement of Tumor Metastasis
The cross-sectional diameter of the largest lymph node metastasis (not the lymph node itself) is measured in the gross specimen at the time of macroscopic examination or, if necessary, on the histologic slide at the time of microscopic examination.

Special Procedures for Lymph Nodes
The risk of regional (cervical neck) nodal spread from cancers varies based on anatomic subsite. At the current time, no additional special techniques are required other than routine histology for the assessment of nodal metastases. Immunohistochemistry and polymerase chain reaction (PCR) to detect isolated tumor cells are considered investigational techniques at this time.

Regional Lymph Nodes (pN0): Isolated Tumor Cells
Isolated tumor cells (ITCs) are single cells or small clusters of cells not more than 0.2 mm in greatest dimension. While the generic recommendation is that for lymph nodes with ITCs found by either histologic examination, immunohistochemistry, or nonmorphologic techniques (eg, flow cytometry, DNA analysis, PCR amplification of a specific tumor marker), they should be classified as N0 or M0, respectively. Evidence for the validity of this practice in head and neck squamous cell carcinoma and other histologic subtypes is lacking. In fact, rare studies relevant to head and neck sites indicate that isolated tumor cells may actually be a poor prognosticator in terms of local control.

Lymph Node Number
Histologic examination of a selective neck dissection specimen will ordinarily include 6 or more lymph nodes. Histologic examination of a radical or modified radical neck dissection specimen will ordinarily include 10 or more lymph nodes in the untreated neck.

Classification of Neck Dissection
1. Radical neck dissection
2. Modified radical neck dissection, internal jugular vein and/or sternocleidomastoid muscle spared
3. Selective neck dissection (SND), as specified by the surgeon (Figure 4), defined by dissection of less than the 5 traditional levels of a radical and modified radical neck dissection. The following dissections are now under this category:
   a. Supraomohyoid neck dissection
   b. Posterolateral neck dissection
   c. Lateral neck dissection
   d. Central compartment neck dissection
4. Superselective neck dissection (SSND), a relatively new term defined by dissection of the fibrofatty elements of 2 or less levels
5. Extended radical neck dissection, as specified by the surgeon

For purposes of pathologic evaluation, lymph nodes are organized by levels as shown in Figure 4.
In order for pathologists to properly identify these nodes, they must be familiar with the terminology of the regional lymph node groups and with the relationships of those groups to the regional anatomy. Which lymph node groups surgeons submit for histopathologic evaluation depends on the type of neck dissection they perform. Therefore, surgeons must supply information on the types of neck dissections that they perform and the details of the local anatomy in the specimens they submit for examination or, in other manners, orient those specimens for pathologists.

If it is not possible to assess the levels of lymph nodes (for instance, when the anatomic landmarks in the excised specimens are not specified), then the lymph node levels may be estimated as follows: level II, upper third of internal jugular (IJ) vein or neck specimen; level III, middle third of IJ vein or neck specimen; level IV, lower third of IJ vein or neck specimen, all anterior to the sternocleidomastoid muscle.

**Level I. Submental Group (Sublevel IA)**
Lymph nodes within the triangular boundary of the anterior belly of the digastric muscles and the hyoid bone.

**Level I. Submandibular Group (Sublevel IB)**
Lymph nodes within the boundaries of the anterior and posterior bellies of the digastric muscle and the body of the mandible. The submandibular gland is included in the specimen when the lymph nodes within this triangle are removed.

**Level II. Upper Jugular Group (Sublevels IIA and IIB)**
Lymph nodes located around the upper third of the internal jugular vein and adjacent spinal accessory nerve extending from the level of the carotid bifurcation (surgical landmark) or hyoid bone (clinical landmark) to the skull base. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the stylohyoid muscle.

**Level III. Middle Jugular Group**
Lymph nodes located around the middle third of the internal jugular vein extending from the carotid bifurcation superiorly to the omohyoid muscle (surgical landmark), or cricothyroid notch (clinical landmark) inferiorly. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.
Level IV. Lower Jugular Group
Lymph nodes located around the lower third of the internal jugular vein extending from the omohyoid muscle superiorly to the clavicle inferiorty. The posterior boundary is the posterior border of the sternocleidomastoid muscle, and the anterior boundary is the lateral border of the sternohyoid muscle.

Level V. Posterior Triangle Group (Sublevels VA and VB)
This group comprises predominantly the lymph nodes located along the lower half of the spinal accessory nerve and the transverse cervical artery. The supraclavicular nodes are also included in this group. The posterior boundary of the posterior triangle is the anterior border of the trapezius muscle, the anterior boundary of the posterior triangle is the posterior border of the sternocleidomastoid muscle, and the inferior boundary of the posterior triangle is the clavicle.

Level VI. Anterior (Central) Compartment
Lymph nodes in this compartment include the pre- and paratracheal nodes, precricoid (Delphian) node, and the perithyroidal nodes, including the lymph nodes along the recurrent laryngeal nerve. The superior boundary is the hyoid bone, the inferior boundary is the suprasternal notch, the lateral boundaries are the common carotid arteries, and the posterior boundary by the prevertebral fascia.

Level VII. Superior Mediastinal Lymph Nodes
Metastases at level VII are considered regional lymph node metastases; all other mediastinal lymph node metastases are considered distant metastases.

Lymph node groups removed from areas not included in the above levels, eg, scalene, suboccipital, and retropharyngeal, should be identified and reported from all levels separately. Midline nodes are considered ipsilateral nodes.

Extranodal Extension
The status of cervical lymph nodes is the single most important prognostic factor in aerodigestive cancer. All macroscopically negative or equivocal lymph nodes should be submitted in toto. Grossly positive nodes may be partially submitted for microscopic documentation of metastasis. Reporting of lymph nodes containing metastasis should include whether there is presence or absence of extranodal extension (ENE),33 which is now part of N staging. This finding consists of extension of metastatic tumor, present within the confines of the lymph node, through the lymph node capsule into the surrounding connective tissue, with or without associated stromal reaction. A distance of extension from the native lymph node capsule is now suggested (but not yet required) with the proposed stratification of ENE into $\text{ENE}_{\text{ma}} (>2 \text{ mm})$ and $\text{ENE}_{\text{mi}} (\leq 2 \text{ mm})$.34-37 However, pitfalls in the measurement (ie, in larger, matted lymph nodes, in nodes post fine-needle aspiration, and in nodes with near total replacement of lymph node architecture), and the disposition of soft tissue deposits is still not resolved. In general, absence of ENE in a large (>3 cm) lymph node, especially with traversing fibrous bands, should be viewed with skepticism. Soft tissue deposits for lymph node metastases based on limited studies appear to be the equivalent of a positive lymph node with ENE and should be recorded as such.38

H. TNM and Stage Groupings
The protocol recommends the TNM staging system of the American Joint Committee on Cancer.2 There are no significant alterations in the 8th edition to T stage of larynx. However, extranodal extension (ENE) is included in N stage. In essence, pathologic ENE(+) will increase the nodal category by 1.

The 8th edition of the AJCC staging of head and neck cancers includes mucosal melanomas; this does not show significant changes from the 7th edition. Approximately two-thirds of mucosal melanomas arise in the sinonasal tract, one-quarter are found in the oral cavity, and the remainder occur only sporadically in other mucosal sites of the head and neck. Even small cancers behave aggressively with high rates of recurrence and death. To reflect this aggressive behavior, primary cancers limited to the mucosa are considered T3 lesions. Advanced mucosal melanomas are classified as T4a and T4b. The anatomic extent criteria to define moderately advanced (T4a) and very advanced (T4b) disease are given below. The AJCC staging for mucosal melanomas does not provide for the histologic definition of a T3 lesion; as the majority of mucosal melanomas are invasive at presentation, mucosal-based melanomas (T3 lesions) include those lesions that involve either the epithelium and/or lamina propria of the
involved site. Rare examples of in situ mucosal melanomas occur, but in situ mucosal melanomas are excluded from staging, as they are extremely rare.39

By AJCC/UICC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.

Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (eg, when technically unfeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

**TNM Descriptors**

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y” and “r” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

- The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.
- The “y” prefix indicates those cases in which classification is performed during or following initial multimodality therapy (ie, neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (ie, before initiation of neoadjuvant therapy).
- The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval, and is identified by the “r” prefix: rTNM.

**Additional Descriptors**

**Residual Tumor (R)**

Tumor remaining in a patient after therapy with curative intent (eg, surgical resection for cure) is categorized by a system known as R classification, shown below.

- RX Presence of residual tumor cannot be assessed
- R0 No residual tumor
- R1 Microscopic residual tumor
- R2 Macroscopic residual tumor

For the surgeon, the R classification may be useful to indicate the known or assumed status of the completeness of a surgical excision. For the pathologist, the R classification is relevant to the status of the margins of a surgical resection specimen. That is, tumor involving the resection margin on pathologic examination may be assumed to correspond to residual tumor in the patient and may be classified as macroscopic or microscopic according to the findings at the specimen margin(s).

**T Category Considerations**

- **Supraglottis.** Normal vocal cord mobility (T1), fixation of the larynx (T2), and vocal cord fixation (T3) may only be determined clinically.

- **Glottis.** Normal vocal cord mobility (T1), impaired vocal cord mobility (T2), and vocal cord fixation (T3) may only be determined clinically.
Subglottis. Normal or impaired vocal cord mobility (T2) and vocal cord fixation (T3) may only be determined clinically.

Stage Groupings: Supraglottis, Glottis, and Subglottis - For All Cancers Except Mucosal Melanoma

<table>
<thead>
<tr>
<th>Stage</th>
<th>Tis</th>
<th>N0</th>
<th>M0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage I</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage II</td>
<td>T2</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage III</td>
<td>T1</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N0, N1</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IVA</td>
<td>T1, T2, T3</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T4a</td>
<td>N0, N1, N2</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IVB</td>
<td>T4b</td>
<td>Any N</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>Any T</td>
<td>N3</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IVC</td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
</tr>
</tbody>
</table>

Stage Groupings – For Mucosal Melanoma

| Stage III | T3  | N0 | M0 |
| Stage IVA | T4a | N0 | M0 |
|           | T3-T4a | N1 | M0 |
| Stage IVB | T4b | Any N | M0 |
| Stage IVC | Any T | Any N | M1 |

I. Dysplasia of the Upper Aerodigestive Tract (UADT)

In contrast to the uterine cervix in which the nonkeratinizing (“classic”) form of epithelial dysplasia is most common resulting in a reproducible and clinically useful grading scheme of mild, moderate, and severe dysplasia (ie, carcinoma in situ), the majority of the UADT mucosal lesions fall under the designation of keratinizing dysplasias, for which the aforementioned criteria are not as easily applied.

The current approach indicated by the WHO for laryngeal precursor lesions is to use a 2-tiered classification of low-grade and high-grade dysplasia. Hyperplasias and keratoses without atypia as well as those with mild dysplasia are categorized as “low grade,” while lesions with moderate and severe dysplasia as well as carcinoma in situ are considered “high grade.” Separation of carcinoma in situ as a distinct category (ie, 3 tiers) is an acceptable option, but data are limited to support this.

Morphologic criteria for the classification of laryngeal precursor lesions are summarized below.

<table>
<thead>
<tr>
<th>Low-grade dysplasia (including previous category of mild dysplasia)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Architectural criteria</td>
</tr>
<tr>
<td>Stratification is preserved; transition of basal cells or augmented basal/parabasal cell layer with perpendicular orientation to the basement membrane to prickle cells horizontally oriented in the upper part</td>
</tr>
<tr>
<td>Spinous layer: spectrum of changes ranging from increased spinous layer in the whole thickness up to changes in which prickle cells are seen only in the upper epithelial half</td>
</tr>
<tr>
<td>Basal/parabasal layer: spectrum of changes, from 2-3 unchanged layers to augmentation of basal and parabasal cells in the lower half of the epithelium</td>
</tr>
<tr>
<td>Cytologic criteria</td>
</tr>
<tr>
<td>At most minimal cellular atypia</td>
</tr>
<tr>
<td>Parabasal cells; slightly increased cytoplasm compared to basal cells, enlarged nuclei, uniformly distributed chromatin, no intercellular bridges</td>
</tr>
<tr>
<td>Rare regular mitoses in or near basal layer</td>
</tr>
<tr>
<td>Few dyskeratotic cells present</td>
</tr>
</tbody>
</table>
### High-grade dysplasia (including previous category of moderate and severe dysplasia, and carcinoma in situ)

<table>
<thead>
<tr>
<th>Architectural criteria*</th>
<th>Cytologic criteria*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abnormal maturation</td>
<td>Easily identified conspicuous cellular and nuclear atypia, including marked variation in size and shape, marked variation in stain intensity with frequent hyperchromasia, nucleoli increased in number and size</td>
</tr>
<tr>
<td>Variable degrees of disordered stratification and polarity in as much as the whole epithelium</td>
<td>Increased N:C ratio</td>
</tr>
<tr>
<td>Altered epithelial cells usually occupying from half to the entire epithelial thickness</td>
<td>Ingreased mitoses at or above the suprabasal level, with or without atypical forms</td>
</tr>
<tr>
<td>Two subtypes: keratinizing (spinous-cell type) and nonkeratinizing (basal-cell type)</td>
<td>Dyskeratotic and apoptotic cells are frequent throughout the entire epithelium</td>
</tr>
<tr>
<td>Variable degree of irregularly shaped rete (bulbous, downwardly extending), with an intact basement membrane</td>
<td></td>
</tr>
<tr>
<td>No stromal alterations</td>
<td>* Complete loss of stratification and polarity and/or severe cytological atypia and atypical mitoses qualifies as carcinoma in situ if a 3-tiered system is used.</td>
</tr>
</tbody>
</table>

The risk of malignant progression in low-grade dysplasia is ~1.6%, while that of high-grade dysplasia is ~12.5%. Limited data suggest that the specific designation of carcinoma in situ carries a risk of 40%.

### References


